Maze Therapeutics CEO Jason Coloma sold 27,858 shares indirectly for approximately $725,000 across June 22 and June 23, 2026, under a prearranged Rule 10b5-1 trading plan adopted in February 2026. The sales reduced his indirect holdings from 372,867 to 345,009 shares, with all shares held through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust. The average transaction price was around $26.04 per share, while the stock closed at $26.41 on June 23, up 134.38% over the past year. Coloma retained over 300,000 shares indirectly, and the company ended the first quarter with $362.9 million in cash, expected to fund operations into 2029 as it advances Phase 2 trials for kidney and metabolic disease therapies.
Maze Therapeutics, Inc. Common StockCEO sold nearly 30,000 shares under a prearranged plan, reducing holdings, which may signal insider sentiment despite the plan being prearranged.